In cost benefit analyses concerned with health related interventions, the monetary cost of developing and implementing a particular intervention is compared to the monetary value of the benefits of that intervention. When a monetary value cannot be given to the major benefits of an intervention, cost effectiveness analysis is more appropriate. In interventions concerned with smoking cessation, cost effectiveness may be expressed in relation to a specific outcome, such as the cost per quitter. A more general approach is to estimate the benefits as the years of life saved by the intervention. Because these years are in the future, they are usually discounted at rates which have varied from 3–10%. Cost effectiveness is then determined as the cost of the intervention per discounted life-year saved. This allows cost related comparisons and decisions to be made between different health related interventions.1,4

Among 32 recently reviewed experimental or quasi-experimental community based interventions which included smoking reduction as one of their aims,7 there were seven with cost effectiveness or cost benefit analyses. Two of these, the North Karelia project and Heartbeat Wales, reported both cost effectiveness and cost benefit analyses related to different aspects of their cardiovascular risk reduction programmes—i.e. the hypertension programme and coronary heart disease disability in the North Karelia Project,6 and smoking reduction in Heartbeat Wales.17 The Norsjo project,16 another cardiovascular risk reduction project, reported cost effectiveness for its cholesterol lowering programme,11 and willingness to pay analyses related to the entire programme.11 Action Heart, another cardiovascular risk reduction project, reported on the cost effectiveness of its programme in reducing smoking.15 Comparison between these cost effectiveness studies, or between the cost benefit studies, are fraught with difficulty largely because of differences in the methods used in each study. However, even with this uncertainty, each project reported either favourable cost effectiveness ratios, in terms of cost per life-year saved, or favourable cost benefit ratios.

Three other analyses, from the Stanford five-city project,14 the Pawtucket heart health programme,13 and the Dutch community study,16 concerned comparisons of the cost effectiveness of different smoking cessation interventions, conducted as part of their respective community programmes, in terms of cost per quitter. The results of each study allowed comparisons within each project as to which particular intervention was more cost effective than another in getting smokers to quit, but do not allow comparisons with other health related interventions.

We previously reported on a significant reduction in the prevalence of cigarette smoking and an increase in the quit rate among adult women, which accompanied a multifaceted, community based intervention targeted to women.7 Logistic regression analyses, adjusting for baseline differences between conditions, showed that after four years, compared to the comparison counties, the odds of being a smoker in the intervention counties were 0.88 (95% confidence interval (CI) 0.78 to 1.00), one tailed p = 0.02.17 The intervention, named Breathe Easy, which involved delivery of cessation services through support systems, health professionals, educators, work sites, and the media, and its evaluation were supported by a research grant from the National Institutes of Health. The research grant costs included the cost of the intervention, the cost of the evaluation, and the University of Vermont’s indirect costs. Herein, we describe the cost effectiveness of that intervention from the perspective of the granting agency. This perspective includes the cost effectiveness of the intervention alone, and the cost effectiveness of the total grant monies awarded to the University of Vermont for this project.

**Objective:** To estimate the cost effectiveness of a four year, multifaceted, community based research project shown previously to help women quit smoking.

**Design:** A quasi-experimental matched control design.

**Setting:** Two counties in Vermont and two in New Hampshire, USA.

**Subjects:** Women aged 18–64 years.

**Methods:** Costs were the grant related expenditures converted to 2002 US$. Survey results at the end of the intervention were used to estimate the numbers of never smokers, former smokers, light smokers, and heavy smokers in the intervention and comparison counties, and 1986 life tables for populations of US women categorised by smoking status to estimate the gain in life expectancy.

**Main outcome measures:** Cost effectiveness ratios, as dollars per life-year saved, for the intervention only and for total grant costs (intervention, evaluation and indirect costs).

**Results:** The cost effectiveness ratio for the intervention, in 2002 US$ per life-year saved, discounted at 3%, was $1156 (90% confidence interval (CI) $567 to $1973), and for the total grant, $4022 (90% CI $1973 to $6683), respectively.

A more general approach is to estimate the benefits as the years of life saved by the intervention. Because these years are in the future, they are usually discounted at rates which have varied from 3–10%. Cost effectiveness is then determined as the cost of the intervention per discounted life-year saved. This allows cost related comparisons and decisions to be made between different health related interventions.1,4

Among 32 recently reviewed experimental or quasi-experimental community based interventions which included smoking reduction as one of their aims,7 there were seven with cost effectiveness or cost benefit analyses. Two of these, the North Karelia project and Heartbeat Wales, reported both cost effectiveness and cost benefit analyses related to different aspects of their cardiovascular risk reduction programmes—i.e. the hypertension programme and coronary heart disease disability in the North Karelia Project,6 and smoking reduction in Heartbeat Wales.17 The Norsjo project,16 another cardiovascular risk reduction project, reported cost effectiveness for its cholesterol lowering programme,11 and willingness to pay analyses related to the entire programme.11 Action Heart, another cardiovascular risk reduction project, reported on the cost effectiveness of its programme in reducing smoking.15 Comparisons between these cost effectiveness studies, or between the cost benefit studies, are fraught with difficulty largely because of differences in the methods used in each study. However, even with this uncertainty, each project reported either favourable cost effectiveness ratios, in terms of cost per life-year saved, or favourable cost benefit ratios.

Three other analyses, from the Stanford five-city project,14 the Pawtucket heart health programme,13 and the Dutch community study,16 concerned comparisons of the cost effectiveness of different smoking cessation interventions, conducted as part of their respective community programmes, in terms of cost per quitter. The results of each study allowed comparisons within each project as to which particular intervention was more cost effective than another in getting smokers to quit, but do not allow comparisons with other health related interventions.

We previously reported on a significant reduction in the prevalence of cigarette smoking and an increase in the quit rate among adult women, which accompanied a multifaceted, community based intervention targeted to women.7 Logistic regression analyses, adjusting for baseline differences between conditions, showed that after four years, compared to the comparison counties, the odds of being a smoker in the intervention counties were 0.88 (95% confidence interval (CI) 0.78 to 1.00), one tailed p = 0.02.17 The intervention, named Breathe Easy, which involved delivery of cessation services through support systems, health professionals, educators, work sites, and the media, and its evaluation were supported by a research grant from the National Institutes of Health. The research grant costs included the cost of the intervention, the cost of the evaluation, and the University of Vermont’s indirect costs. Herein, we describe the cost effectiveness of that intervention from the perspective of the granting agency. This perspective includes the cost effectiveness of the intervention alone, and the cost effectiveness of the total grant monies awarded to the University of Vermont for this project.
METHODS
The Breathe Easy project was undertaken in four counties, two in Vermont and two in New Hampshire. One county in each state received the intervention, while the other pair of demographically similar counties was the comparison area. The four year intervention and its efficacy, which was assessed by random digit dialling telephone surveys at baseline and year 5, at the end of the intervention, have been described in detail elsewhere.\(^{17–22}\) The costs of intervention development, implementation, and evaluation were derived from the actual expenditures of grant monies for these components of the research project. We summed the portion of salaries and fringe benefits of investigators and staff and the project operating expenditures related to each component for each of the five years. Intervention costs were the sum of development and implementation expenditures, and direct costs were the sum of intervention and evaluation expenditures. Indirect costs were those received by the University of Vermont to cover the general costs of supporting research, such as grant administration, heating, lighting, and security. Total grant costs were the sum of direct and indirect costs.

We used the consumer price index (CPI) to adjust all costs to 2002 US dollars (US$2002), using the ratio of the 2002 CPI to the CPI for each of the years 1989–1993.\(^{21}\) In addition, all costs reported in the cost effectiveness studies referred to subsequently were adjusted to US$2002, using the ratio of the 2002 CPI to the CPI for the year of the reported costs in each study.

Population estimates
We used the smoking behavioural results of the year 5 survey\(^{23}\) and 1990 census population data for the two intervention counties to estimate the numbers of female never smokers, former smokers (> 3 years and ≤ 5 years), light smokers (< 25 cigarettes per day), and heavy smokers (> 25 cigarettes per day), ages 18–64 years, in five year age strata, except for seven years in the 18–24 year age group, using SUDANN software.\(^{24}\) These estimates were done for women in the intervention counties and in a modified comparison area constrained to have the same population and age distribution as the intervention counties, but the year 5 smoking behavioural results of the comparison counties.

Estimates of life expectancy
We used Microsoft Access to build a Monte Carlo life table model.\(^{25}\) This model used the number of women in each smoking category in each age group derived from our estimates of their respective population means and standard errors. We used published 1986 life tables for white female never, former, light, and heavy smokers to calculate the life expectancy for each smoking category in each age cohort.\(^{26}\) As the life table model runs, each age cohort with its smoking related categories is cycled to the next higher age stratum and then experiences the appropriate mortality rates of that stratum. This cyclical process continues upwards through each of the age strata in the life tables. The reference life tables do not include mortality data for the 18–24 year age group. For this age cohort, in the base analysis, we assumed that there was no smoking related effect on life expectancy between ages 18 to 24 years, and used the 1986 mortality rate of white females for these ages from US Vital Statistics,\(^{27}\) regardless of this cohort’s smoking status. When this cohort cycled up through the subsequent age strata, it experienced their appropriate smoking related mortality rates. The reference life tables also do not distinguish between recent and longer term quitters, so we regarded both categories as former smokers.

We used 10 000 cycles of the model to determine the life expectancy for both the intervention and comparison populations. For the base case, life-years saved were discounted at 3%.\(^{28}\) Cost effectiveness ratios were then calculated as the cost per life-year saved for intervention costs and for total grant costs.

Sensitivity analyses
We conducted several sensitivity analyses. Because we lacked mortality data for the 18–24 year old cohort, we did two further estimates—one to provide a more favourable mortality experience for this age cohort than the base case, and the other a less favourable experience. For the first of these, we substituted zero mortality for the 18–24 year cohort until they cycled into the 25–29 year age stratum. For the second, we substituted the known mortality of each smoking category in the 25–29 year age stratum for the unknown mortality of the 18–24 year cohort, which then cycled up the age strata. In additional sensitivity analyses, we examined discount rates of 0% and 5%; indirect cost recovery rates of 10% and 25%; and community volunteer opportunity costs of $10/hour and $25/hour.

Level of significance
In reporting the results of the Breathe Easy project, a one tailed test of significance was used to assess differences between conditions, because the a priori main hypothesis was that more favourable changes would be observed in the intervention counties relative to the comparison counties.\(^{17}\) We have used that convention here.

RESULTS
Personnel effort
The full time equivalent (FTE) effort provided by faculty and staff at the University of Vermont during this research project (April 1989 through July 1993) was 8.3 (investigators, 1.8 FTE; research staff, 4.9 FTE; administrative staff, 1.6 FTE). Each of the two intervention counties had a community office staffed by three full time employees (a community coordinator, a health educator, and a secretary); thus the overall total staffing for the research group was 14.3 FTE.

Costs
All costs, derived from project expenditure records, were converted to US$2002. For intervention development and implementation, personnel salaries and fringe benefits were $1 348 257, consultant costs, $29 799, and operating costs, $593 424, for total intervention costs of $1 971 480. For evaluation, personnel salaries and fringe benefits were $2 297 467, consultant costs, $654 447, and operating costs, $307 895, for a total of $2 611 906. Direct costs, the sum of intervention and evaluation costs, were $4 583 386. Indirect costs were $2 273 756, so that total grant costs—that is, the sum of direct and indirect costs—were $6 857 142.

Population estimates
The population of women in the two intervention counties was 35 243. Our estimates of the number of never smokers, former smokers (> 5 years and ≤ 5 years), light smokers, and heavy smokers in the intervention counties and modified comparison area in 1993, at the end of the intervention, are shown in table 1.

Cost effectiveness
The life-years saved with no discounting and with 3% and 5% discounting are shown in table 2. Life-years saved with no discounting and those at 3% discounting were not significant, while those at 5% discounting were significant \((p = 0.04)\).
Table 1 also shows the cost effectiveness ratios of this research project—that is, dollars per life-year saved—in relation to intervention costs, direct costs, and total grant costs, with no discounting and with 3% and 5% discounting. For both no discounting and 3% discounting, the 90% confidence intervals included zero, leading to infinity for the upper limit of the related cost effectiveness ratios. The lower limit of the 90% confidence interval with 3% discounting was −65 years, while that with 5% discounting was 126 years.

**Sensitivity analyses**

In estimating life expectancy for the 18–24 year age cohort for the base case analysis, we used mortality rates for white females from the 1986 US life tables without regard to smoking status. Substituting zero probability of death for this age group until they reach 25–29 years, regardless of smoking status, a liberal assumption, increased the 18–24 year age cohort’s life-years saved by 75 years compared to the base case, and reduced the cost effectiveness ratios by 4.2%. Substituting the mortality experience of the 25–29 year age group, a conservative assumption, reduced the 18–24 year age cohort’s life-years saved by 20 years compared to the base case, and increased the cost effectiveness ratios by 1.2%.

This study was funded by the National Institutes of Health. The University of Vermont’s indirect cost rate at that time was about 50%. For grants from non-profit agencies, indirect cost recovery rates are usually substantially less than this, between 10–25%. The cost effectiveness of the intervention alone, without evaluation, and of the intervention and evaluation combined with indirect costs at 10% and 25%, with 3% and 5% discounting, are shown in table 3. As would be expected, the ratios increase in proportion to the increase in costs.

Because our analysis was from the perspective of the granting agency, we did not include the opportunity costs of the numerous community volunteers who assisted with many aspects of intervention implementation in the base analysis. However, the time contributed by volunteers during the course of the project was at least 7500 hours, as determined from each community’s monthly reports (Secker-Walker RH, unpublished data). At $10/hour, these volunteer hours would add $78 250 to the intervention costs, an increase of 5%, and at $25/hour they would add $245 625, an increase of 12.5%. The cost effectiveness of the intervention alone, without evaluation, and of the total grant, with volunteer opportunity costs of $10/hour and $25/hour, with 3% and 5% discounting, are shown in table 3. The ratios increase in proportion to the increase in costs.

**DISCUSSION**

The cost effectiveness ratios of Breathe Easy’s community based smoking cessation intervention alone and of the research grant as a whole are economically attractive, although those obtained with 3% discounting, the recommended rate,24 fell short of conventional statistical significance. In this study, the 90% confidence interval for the increase in life-years saved with 3% discounting ranged from −65 to 3475 years. Thus, although the mean cost effectiveness ratios and lower 90% confidence intervals for the intervention alone and for the total grant at this discount rate could be estimated, the upper limit could not. We note that the probability that life-years saved was greater than zero, and hence the upper limit of the cost effectiveness ratios was finite, was 94%.

Although the currently recommended discount rate for cost effectiveness analyses is 3%, a sensitivity analysis using 5% is also recommended because many earlier cost effectiveness analyses used that rate.28 In this study, the increase in life-years saved with 5% discounting was significant, the 90% confidence interval ranging from 126 to 1926 years. We note that three contemporary community based studies, two aimed at smoking cessation, the Stockholm Quit and Win Contest (1988),29 and Action Heart (1991–1995),30 and the other at lowering cholesterol, the Norsjo project (1985–1990),27 used discount rates of 5%, 6%, and 5%, respectively, in their cost effectiveness analyses.

This cost effectiveness analysis was from the perspective of the granting agency which funded this community based health education research project. Such granting agencies have a substantial interest in dissemination of successful projects. If the Breathe Easy intervention was widely adopted in other communities, the benefits of the investment in the research aspects of the project—that is, its evaluation—would extend beyond those achieved during this project. The inclusion of evaluation costs and indirect costs in our analysis, as others have done,28 overstates the cost per life-year saved that would result from replications of the intervention itself. A community based smoking cessation programme would incur local development and implementation costs,
and modest indirect costs, and, if successful, could be as cost effective as the Breathe Easy intervention alone—that is, with cost effectiveness ratios between $1000–$2000 per life-year saved.

We used published life tables from 1986, the latest we could find with detailed smoking related mortality rates, to estimate life expectancy. These life tables predate the year 5 Breathe Easy survey by seven years. Since that time, the life expectancy of women has increased, so it is likely that the cost effectiveness of both the intervention alone and of the total grant would have been more favourable than our estimates.

### Sensitivity analyses

Our base case estimate for the unknown mortality experience of the 18–24 year old cohort seems quite reasonable, giving a cost effectiveness ratio 4.2% greater than the “no mortality” estimate, and only 1.2% lower than that obtained using the smoking related mortality rates of the 25–29 year age group.

The other sensitivity analyses, related to indirect costs and volunteer opportunity costs, show the expected changes in cost effectiveness ratios in proportion to the increases in costs, resulting in relatively small changes to the cost effectiveness of the Breathe Easy project. For example, with 3% discounting, the mean cost effectiveness of the intervention alone, with indirect costs at 25%, was $1445 per life-year saved, and with volunteer opportunity costs at $25/hour, the mean cost effectiveness ratio was $1300 per life-year saved.

### Limitations

There are several limitations to our analyses, some of which relate to the design of the original trial. First, the sample size for the original research project was not calculated with this cost effectiveness analysis in mind. Although there were 6436 respondents to the year 5 survey, the number in each of the five smoking categories in each of the nine age strata in each condition, from which the population estimates were made, was small, averaging 71.5 per cell (SD 71.0). Thus, the standard errors of these estimates were relatively large, contributing to the lack of significance of the life-years saved with 0% and 3% discounting. Second, this was a quasi-experimental, non-randomised design with only two pairs of matched communities in each condition. Randomised designs with eight or more matched pairs of communities, such as COMMIT and CART, allow for more robust analyses. Third, we did not include an estimate of life-years gained by non-smoking community members as a result of less exposure to secondhand smoke, thereby overstating, to a small extent, the cost per life-year saved of the Breathe Easy project.

### Strengths

There are several strengths to this study. First, we estimated life-years saved from published life tables for the intervention and modified comparison counties’ populations, rather than the median, or a range of differences in life expectancy between smokers and non-smokers as used by others. Second, for the original trial, the statistical comparisons matched the design—that is, the communities were the unit of analysis. Third, the observed fall in smoking prevalence in the intervention counties was unlikely to be caused by secular trends. Most of the reduction in smoking took place among groups of women specifically targeted by the intervention, those with lower incomes and of childbearing age.

### Comparisons with other studies

Cost effectiveness ratios for smoking cessation interventions tend to be greater for women than men. As far as we are aware, the Breathe Easy Project is the only community based smoking reduction intervention specifically targeted to women for which there are published results, which makes direct comparison with other studies difficult. Although the Canadian trial, Coeur en Sante St Henri, a cardiovascular risk reduction project, had a special focus on women, there was no effect on smoking prevalence and no cost effectiveness analysis.

As shown in table 4, the mean cost effectiveness ratios for the Breathe Easy Project are similar to those obtained for smoking cessation advice for women provided by physicians, and for the transdermal nicotine patch as an adjunct to physicians’ advice, but substantially less than the use of nicotine gum as an adjunct to physicians’ advice. Our cost effectiveness ratios are also similar to those reported for implementation of the Agency for Health Care Policy and Research (AHCPR) guidelines for smoking cessation interventions for both women and men. Strict comparison between these studies must be tempered by their use of

---

### Table 3: Results of sensitivity analyses

<table>
<thead>
<tr>
<th>Indirect costs</th>
<th>3% discount rate</th>
<th>5% discount rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>$/LYS (90% CI)</td>
<td>$/LYS (90% CI)</td>
<td>$/LYS (90% CI)</td>
</tr>
<tr>
<td>10%</td>
<td>Intervention</td>
<td>1272 (624 to =)</td>
</tr>
<tr>
<td>25%</td>
<td>Intervention</td>
<td>1445 (709 to =)</td>
</tr>
<tr>
<td>10%</td>
<td>Total grant</td>
<td>4424 (2171 to =)</td>
</tr>
<tr>
<td>25%</td>
<td>Total grant</td>
<td>5027 (2467 to =)</td>
</tr>
</tbody>
</table>

Volunteer costs

| $/hour | Intervention | 1214 (596 to =) | 2017 (1075 to 16426) |
| $/hour | Intervention | 1300 (638 to =) | 2161 (1151 to 17596) |
| $/hour | Total grant | 4079 (2002 to =) | 6779 (3611 to 55202) |
| $/hour | Total grant | 4166 (2044 to =) | 6923 (3688 to 55372) |

### Table 4: Cost effectiveness ratios for smoking cessation trials

<table>
<thead>
<tr>
<th>Smoking cessation intervention</th>
<th>Discount rate (%)</th>
<th>US$2002 per life-year saved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians’ advice, 1984*</td>
<td>5</td>
<td>2094–3581</td>
</tr>
<tr>
<td>Physicians’ advice, 1984*</td>
<td>5</td>
<td>11971–16483</td>
</tr>
<tr>
<td>Plus nicotine gum, 1995**</td>
<td>3</td>
<td>5847–82401</td>
</tr>
<tr>
<td>AHCPR guidelines, 1995*</td>
<td>3</td>
<td>1307–53501</td>
</tr>
<tr>
<td>Stockholm Quit and Win contest, 1988***</td>
<td>5</td>
<td>1671–3749</td>
</tr>
<tr>
<td>Present study—Breathe Easy, 2002</td>
<td>3</td>
<td>1156–4022</td>
</tr>
<tr>
<td>Present study—Breathe Easy, 2002</td>
<td>5</td>
<td>1922–6683</td>
</tr>
</tbody>
</table>

*For women; †for women and men; ‡US$2002 quality adjusted life-years saved.

---

www.tobaccocontrol.com

---

differing discount rates, 5% in the earlier ones,\textsuperscript{37} \textsuperscript{38} and 3% in the later ones,\textsuperscript{39} \textsuperscript{41} and also the use of quality adjusted life-years saved in two of them.\textsuperscript{39} \textsuperscript{41}

Among community based interventions, Action Heart has reported on the cost effectiveness of its cardiovascular risk reduction programme in relation to smoking.\textsuperscript{11} This project, which took place in the UK from 1991–1995, had modest intervention costs, $\sim$187 150, and reported a reduction in adult smoking prevalence of 3.4 percentage points in the two intervention communities, and an increase of 1.6 percentage points in the reference community. Cost effectiveness ratios were $\sim$53 per life-year gained, without discounting, and $\sim$201 per life-year gained discounted at 6%.

These impressive results must be tempered by the paucity of detail provided about the content of the low cost, community based intervention, and also by the lack of comparability in baseline smoking prevalence and socioeconomic indicators between the two intervention communities and the reference community, with the reference community having a higher prevalence of smoking (36.4% \textpm 32.2%) and lower socioeconomic indicators.\textsuperscript{42} It seems likely that secular trends may have played a major role in the changes in smoking prevalence which occurred during this project.\textsuperscript{42} Similar trends in smoking prevalence were seen in the comparison counties in Heartbeat Wales between 1985 and 1990, and in the UK between 1996 and 2001.\textsuperscript{2} \textsuperscript{43}

Cost effectiveness ratios, in terms of costs per working life-year saved, have been reported for Heartbeat Wales in relation to its smoking reduction programme, $\sim$13–$133, but these analyses assumed no change in prevalence in the absence of the intervention.\textsuperscript{39} We note that during that programme, smoking prevalence decreased slightly more in the comparison counties than in Wales, and analyses at both individual and community levels showed no significant intervention effect for smoking, precluding a cost effective analysis of this aspect of Heartbeat Wales as a research project.\textsuperscript{47}

The cost effectiveness of a one year community anti-smoking campaign targeted at Turkish speaking people in London has also been reported.\textsuperscript{14} However, this was a pre-post design with no comparison group, so that the estimates of cost per life-year gained without discounting, $\sim$173 (range 55–633), do not take into account potential secular changes in smoking prevalence in the absence of the intervention.

The cost effectiveness of smoking cessation programmes, conducted as part of broader community based interventions, has been reported from four studies,\textsuperscript{15–16} \textsuperscript{23} but for only one of these, the Stockholm Quit and Win Contest, were the results reported in terms of costs per life-year saved.\textsuperscript{23} This contest was part of a countywide intervention and combined a national mass media programme with countywide recruitment of participants through local organisations. The cost effectiveness analysis used intervention and evaluation costs, and estimates of the number of quitters based on reported quit rates at a 12 month follow up survey among participants. The cost per life-year saved, discounted at 5%, ranged from $1671 to $3749.

Among the other community based based projects with economic analyses, the cost effectiveness of the North Karelia project’s 1972–1977 hypertension control programme, discounted at 5%, was $\sim$16 568,\textsuperscript{8} while that of the first six years (1985–1990) of the Norsjo project’s cholesterol lowering programme, discounted at 5%, was $\sim$3168–$7776.\textsuperscript{6} Reports of the cost effectiveness of other hypertension and cholesterol screening and treatment programmes have shown a wide range of values,\textsuperscript{30} \textsuperscript{34} \textsuperscript{44} \textsuperscript{45} with some cholesterol lowering programmes having cost effectiveness ratios greater than $100 000 per life-year saved.\textsuperscript{30} \textsuperscript{44} \textsuperscript{45}

ACKNOWLEDGEMENTS

We thank Alison Bell, BA, for her invaluable help in abstracting and categorising the original cost data for these analyses, and Joan M Skelly, MS, for the population estimates of the numbers of never, former, light, and heavy smokers. Supported by the National Institutes of Health, grants HL40685 and CA22435.

Authors’ affiliations

R H Secker-Walker*, R R Holland, C M Lloyd, D Pelkey, B S Flynn, The Office of Health Promotion Research, University of Vermont, Burlington, Vermont, USA

* Also the Vermont Cancer Center, University of Vermont

†Also the Vermont Cancer Center, and the Department of Family Practice, University of Vermont

Preliminary results of the cost effectiveness of the Community Coalitions to Help Women Quit Smoking Project were part of an invited presentation to the University of Edinburgh, Department of Community Health Sciences Seminar Series, 3 May 1999, Edinburgh, UK

REFERENCES


www.tobaccocontrol.com

www.tobaccocontrol.com
Cost effectiveness of a community based research project to help women quit smoking

R H Secker-Walker, R R Holland, C M Lloyd, D Pelkey and B S Flynn

Tob Control 2005 14: 37-42
doi: 10.1136/tc.2003.005470

Updated information and services can be found at:
http://tobaccocontrol.bmj.com/content/14/1/37

These include:

References
This article cites 32 articles, 5 of which you can access for free at:
http://tobaccocontrol.bmj.com/content/14/1/37#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/